Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
Glucosylceramide Synthase (GCS)
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "Glucosylceramide Synthase (GCS)" in MCE Product Catalog:
3
3 Cited Publications
Cat. No.: HY-16743
CAS No.: 1401090-53-6
Synonyms: Venglustat; SAR402671; GZ402671
Target:
Research Areas:
Ibiglustat (Venglustat) is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
3
3 Cited Publications
Cat. No.: HY-16743A
CAS No.: 1629063-78-0
Synonyms: Venglustat (L-Malic acid); SAR402671 (L-Malic acid); GZ402671 (L-Malic acid)
Target:
Research Areas:
Ibiglustat (Venglustat) L-Malic acid is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat L-Malic acid can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
3
3 Cited Publications
Cat. No.: HY-16743B
CAS No.: 1629063-80-4
Synonyms: Venglustat succinate; SAR402671 succinate; GZ402671 succinate
Target:
Research Areas:
Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
Synonyms: NB-DGJ; N-(n-Butyl)deoxygalactonojirimycin
Target:
Research Areas:
Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study .
Research Areas:
DL-threo-PDMP hydrochloride is a competitive glucosylceramide synthase (GCS) inhibitor and antimalarial agent. DL-threo-PDMP hydrochloride competitively inhibits the activity of GCS. DL-threo-PDMP hydrochloride restores cisplatin sensitivity in cisplatin-resistant testicular germ cell tumor cells. DL-threo-PDMP hydrochloride blocks the growth of ring-stage Plasmodium falciparum parasites .
Cat. No.: HY-116392D
CAS No.: 73257-80-4
Research Areas:
PDMP hydrochloride is a glucosylceramide synthase (GCS) inhibitor. PDMP hydrochloride induces apoptosis in K562/A02 cells. PDMP hydrochloride can be used in cancer (such as leukemia) research .
Synonyms: ACT-519276; OGT2378
Target:
Research Areas:
Sinbaglustat (OGT2378) is a dual inhibitor of glucosylceramide synthase (GCS) and non-lysosomal glucosyl ceramidase (GBA2). Sinbaglustat is an orally available N-alkyl iminosugar that crosses the blood-brain barrier. Sinbaglustat can be used for the research of central neurodegenerative diseases associated with lysosomal dysfunctions .
Synonyms: Glucosylceramide Synthase-IN-1
Target:
Research Areas:
Glucosylceramide synthase-IN-1 (T-036), a chemical probe, a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 31 nM and 51 nM for human GCS and mouse GCS, respectively. Glucosylceramide synthase-IN-1 can be used for Gaucher's disease research .
Target:
Research Areas:
Glucosylceramide synthase-IN-2 (compound T-690) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 15 nM and 190 nM for human GCS and mouse GCS, respectively.Glucosylceramide synthase-IN-2 exhibits noncompetitive type inhibition with C8-ceramide and UDP-glucose.Glucosylceramide synthase-IN-2 can be used for Gaucher's disease research .
Cat. No.: HY-144270
CAS No.: 3029827-91-3
Target:
Research Areas:
Glucosylceramide synthase-IN-3 (compound BZ1) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 16 nM for human GCS.Glucosylceramide synthase-IN-3 can be used for Gaucher's disease research .
Cat. No.: HY-112488
CAS No.: 1239893-96-9
Target:
Research Areas:
EXEL-0346 is an orally active glucosylceramide synthase (GCS) inhibitor, with an IC50 of 2 nM. EXEL-0346 combined with insulin increases pAkt. EXEL-0346 effectively reduces the levels of Glucosylceramide, Lactosylceramide and GM3. EXEL-0346 improves obesity and diabetes .
Cat. No.: HY-163131
CAS No.: 2776965-41-2
Target:
Research Areas:
Glucosylceramide synthase-IN-4 (compound 12) is a potent glucosylceramide synthase (GCS) inhibitor, with an IC50 of 6.8 nM. Glucosylceramide synthase-IN-4 shows excellent PK properties and stability in human hepatocytes. Glucosylceramide synthase-IN-4 has good CNS penetration and acceptable PXR selectivity .
Cat. No.: HY-106392R
CAS No.: 141206-42-0
Synonyms: NB-DGJ (Standard); N-(n-Butyl)deoxygalactonojirimycin (Standard)
Research Areas:
Lucerastat (Standard) is the analytical standard of Lucerastat. This product is intended for research and analytical applications. Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS). Lucerastat has the potential for Fabry disease study .
Cat. No.: HY-116392A
CAS No.: 161491-04-9
Target:
Research Areas:
(−)-L-threo-PDMP hydrochloride is the hydrochloride form of (−)-L-threo-PDMP. L-threo-PDMP is a glucosylceramide synthase (GCS) inhibitor. L-threo-PDMP stimulates the proliferation of cultured aortic smooth muscle cells, and that increases the level of LacCer in B16 melanoma cells .
Cat. No.: HY-16743C
CAS No.: 1629063-79-1
Synonyms: Venglustat hydrochloride; SAR402671 hydrochloride; GZ402671 hydrochloride
Target:
Research Areas:
Ibiglustat hydrochloride is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat hydrochloride can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease .
Cat. No.: HY-186121
CAS No.: 3118501-69-9
Target:
Research Areas:
Glucosylceramide synthase-IN-5 (G3-3) is a glucosylceramide synthase (GCS) inhibitor that can be used for the study of the diseases and disorders associated with GCS activity, such as lysosomal storage disorders .
Cat. No.: HY-186121A
CAS No.: 3118501-71-3
Target:
Research Areas:
Glucosylceramide synthase-IN-6 (G3-3B) is a glucosylceramide synthase (GCS) inhibitor that can be used for the study of the diseases and disorders associated with GCS activity, such as lysosomal storage disorders .
Cat. No.: HY-206259
CAS No.: 1430611-23-6
Target:
Research Areas:
CCG-203586 is a brain-penetrant glucosylceramide synthase (GCS) inhibitor. CCG-203586 reduces GCS production and brain levels, blocks the first committed step in ganglioside biosynthesis, and lowers downstream ganglioside levels. CCG-203586 can be used for the research of Tay-Sachs, Sandhoff disease, and types 2 and 3 Gaucher disease .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
